SCHEMBL3884732

SCHEMBL3884732

Cc1cccnc1N1CCN(c2cc(-c3ccc4ccccc4c3)nc(N3CCOCC3)n2)[C@H](C)C1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 4/20 0.42
PIK3CA P42336 7/20 0.41
DKK1 O94907 2/20 0.39
MAP3K12 Q12852 1/20 0.38
MTOR P42345 4/20 0.38
KDM4E B2RXH2 2/20 0.37
LMNA P02545 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PIK3R1 P27986 1/20 0.37
GBA1 P04062 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3879904 0.91 TRPV1 (0.43) TRPV1PIK3CAMAP3K12MTORKDM4E
SCHEMBL3877080 0.91 TRPV1 (0.46) TRPV1PIK3CADKK1MAP3K12MTOR
SCHEMBL3881431 0.90 TRPV1 (0.42) TRPV1PIK3CAMAP3K12MTORKDM4E
SCHEMBL3879587 0.89 TRPV1 (0.42) TRPV1PIK3CAMAP3K12MTORKDM4E
SCHEMBL13766119 0.89 TRPV1 (0.43) TRPV1PIK3CAMAP3K12MTORKDM4E
SCHEMBL3882209 0.89 MTOR (0.45) TRPV1PIK3CAMAP3K12MTORKDM4E
SCHEMBL3891337 0.88 TRPV1 (0.46) TRPV1PIK3CAMTORKDM4ETDP1
SCHEMBL3878243 0.88 GRM1 (0.40) PIK3CADKK1MAP3K12MTORMAPT
SCHEMBL3888123 0.87 PIK3CA (0.43) TRPV1PIK3CAMAP3K12MTORKDM4E
SCHEMBL3879034 0.87 CYP1A2 (0.51) TRPV1PIK3CAMTORKDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues GPR174, GPR68, PPARG TRPV1 244/4885PIK3CA 1107/4885DKK1 4253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.